(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Genetic Pharmacology Service (GPS) team at Cincinnati Children's Hospital Medical Center is comprised of specialists in molecular genetics, neurology and pharmacology research.
Tracy A. Glauser, MD Associate Director, Cincinnati Children's Research Foundation 513-636-4222 firstname.lastname@example.org
Associate Director, Cincinnati Children's Research Foundation
Director, Comprehensive Epilepsy Center
Co-Director, Genetic Pharmacology Service
Professor, UC Department of Pediatrics
Epilepsy; pharmacogenetics; clinical pharmacology
Tracy A. Glauser, MD, is director of the Comprehensive Epilepsy Center and co-director of the Genetic Pharmacology Service at Cincinnati Children’s Hospital Medical Center and professor of pediatrics in the University of Cincinnati College of Medicine. Dr. Glauser received his medical degree, cum laude, from Jefferson Medical College in Philadelphia, PA. He completed his residency in pediatrics at the John Hopkins Hospital in Baltimore, MD, and fellowship in child neurology at The Children’s Hospital of Philadelphia, University of Pennsylvania in Philadelphia, PA. Dr. Glauser completed a National Institute of Neurological Disorders and Stroke research fellowship in pediatric neurology and was a fellow in epilepsy and electroencephalography at St. Louis Children’s Hospital, Washington University School of Medicine in St. Louis, Missouri.
Dr. Glauser has authored and co-authored more than 130 articles and book chapters, been involved with the development of 6 evidence based guidelines about epilepsy therapy and given over 150 invited lectures throughout the world. He has been the principal investigator on multiple NIH grants. Currently, Dr. Glauser directs the NIH funded Childhood Absence Epilepsy clinical trial involving 32 pediatric centers around the United States. Dr. Glauser’s fields of expertise are pediatric neurology, pediatric epilepsy, clinical pharmacology and pharmacogenetics.
MD: Jefferson Medical College, Philadelphia, PA, 1985.
Residency: Johns Hopkins Hospital, Baltimore, MD.
Fellowship: St. Louis Children's Hospital, St. Louis, MO.
Certification: Pediatrics, 1990; Neurology (with special competence in child neurology), 1991.
Modi AC, Guilfoyle SM, Morita DA, Glauser TA. Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy. Epilepsia. 2010 Nov 18. doi: 10.1111/j.1528-1167.2010.02789.x.
Modi AC, Monahan S, Daniels D, Glauser TA. Development and validation of the Pediatric Epilepsy Medication Self-Management Questionnaire. Epilepsy Behav. 2010 May;18(1-2):94-9
Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.
Holland KD, Monahan S, Morita D, Vartzelis G, Glauser TA. Valproate in children with newly diagnosed idiopathic generalized epilepsy. Acta Neurol Scand. 2010 Mar;121(3):149-53.
Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29.
Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94.
Modi AC, King AS, Monahan SR, Koumoutsos JE, Morita DA, Glauser TA. Even a single seizure negatively impacts pediatric health-related quality of life. Epilepsia. 2009 Sep;50(9):2110-6.
Daniels ZS, Nick TG, Liu C, Cassedy A, Glauser TA. Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy. Neurology. 2009 Sep 1;73(9):658-64.
Glauser TA, Sankar R; Co-chairs of the Leadership in Epilepsy, Advocacy, and Development Faculty. Core elements of epilepsy diagnosis and management: expert consensus from the Leadership in Epilepsy, Advocacy, and Development (LEAD) faculty. Curr Med Res Opin. 2008 Dec;24(12):3463-77.
Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 May 20;70(21):1950-8.
Alexander (Sander) A. Vinks, PharmD, PhD, FCP Director, Division of Clinical Pharmacology 513-636-0159 email@example.com
Director, Division of Clinical Pharmacology
Scientific Director, Pharmacy Research, Research in Patient Services
Adjunct Professor of Pharmacology
Sander Vinks, PharmD, PhD, FCP, is a professor of pediatrics and pharmacology at the University of Cincinnati, College of Medicine. He is the director of the Division of Clinical Pharmacology, and serves as director of the Pediatric Clinical and Developmental Pharmacology NIH T32 training program since 2011. He is co-director of Cincinnati Children’s Genetic Pharmacology Service, and scientific director for pharmacy research in the Division of Patient Services. He also directs the Laboratory of Applied Pharmacokinetics and Pharmacogenetics (LAPP) and a multidisciplinary Pharmacometrics Core. Dr. Vinks also serves as an advisor on an FDA pediatric sub-committee.
Dr. Vinks is the past president of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. He serves on the Board of Regents of the American College of Clinical Pharmacology and is chair of the Clinical Pharmacology and Translational Research Committee of the American Association of Pharmaceutical Scientists. He has served as the principal investigator of the former NICHD Pediatric Research Unit at Cincinnati Children’s Hospital Medical Center.
His major research interests include personalized and precision medicine, pharmacokinetic-pharmacodynamic (PK/PD) modeling, physiologically based pharmacokinetics (PBPK), pharmacogenetics/genomics (PG) and the application of genomic, population and simulation approaches (pharmacometrics) to pediatric trial design and therapeutic drug management.
Dr. Vinks has presented his research as an invited speaker in 220 national and international conferences, has published over 140 peer reviewed manuscripts and 18 book chapters and has presented more than 150 abstracts. He is associate editor of Clinical Pharmacology & Therapeutics. Dr. Vinks is both board certified in clinical pharmacology and toxicology and is a fellow of the American College of Clinical Pharmacology.
Certification: American Board of Clinical Pharmacology, 2001.
PhD: Clinical Pharmacology, Leiden University, Leiden The Netherlands, 1996.
PharmD: Hospital Pharmacy, The Hague Central Hospital Pharmacy, The Hague, The Netherlands, 1986.
MS: Pharmacology, University of Toronto, Toronto Canada, 1983.
MS: Pharmacy, Leiden University, Leiden, The Netherlands, 1981.
Wiles JR, Isemann B, Ward LP, Vinks AA, Akinbi H. Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. J Pediatr. 2014 Sep;165(3):440-6.
Hahn A, Frenck RW Jr, Zou Y, Vinks AA. Validation of a Pediatric Population Pharmacokinetic Model for Vancomycin. Ther Drug Monit. 2014 Nov 21.
Nehus EJ, Mouksassi S, Vinks AA, Goldstein S. Meropenem in Children Receiving Continuous Renal Replacement Therapy: Clinical Trial Simulations Using Realistic Covariates. Journal Clin Pharmacology. 2014 Dec;54(12):1421-1428.
Smits TA, Cox S, Fukuda T, Sherbotie JR, Ward RM, Goebel J, Vinks AA. Effects of unbound mycophenolic Acid on inosine monophosphate dehydrogenase inhibition in pediatric kidney transplant patients. Ther Drug Monit. 2014 Dec;36(6):716-23.
Dong M, Fukuda T, Cox S, de Vries MT, Hooper DK, Goebel J, Vinks AA. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. Br J Clin Pharmacol. 2014 Nov;78(5):1102-12.
Rasmussen-Torvik LJ, Stallings SC, Gordon AS, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther. 2014 Oct;96(4):482-9.
Emoto C, Fukuda T, Mizuno T, Cox S, Schniedewind B, Christians U, Widemann BC, Fisher MJ, Weiss B, Perentesis J, Vinks AA. Age dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. Ther Drug Monitoring. 2014 Aug 26.
Venkatasubramanian R, Fukuda T, Niu J, Mizuno T, Chidambaran V, Vinks AA, Sadhasivam S. ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics. 2014 Jul;15(10):1297-309.
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL; on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualized antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun;14(6):498-509.
Kejian Zhang, MD, MBA Director, Molecular Genetics Laboratory 513-636-0121 firstname.lastname@example.org
Director, Molecular Genetics Laboratory
Associate Professor, UC Department of Pediatrics
Molecular genetics diagnosis of inherited immunodeficiency disorders and other genetic conditions
MD: Tianjin Medical University, Tianjin, China, 1993.
MBA: College of Business Administration, University of Cincinnati, Cincinnati, OH, 2001.
Residency: Gong'an Hospital, Tianjin, China, 1993-1995.
Fellowship: Clinical Molecular Genetics Fellow, Division of Human Genetics, Cincinnati Children's Hospital, 2002-2004.
Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, Zhang Y, Liu Z, Fritz JM, Marsh R, Husami A, Kissell D, Nortman S, Chaturvedi V, Haines H, Young LR, Mo J, Filipovich AH, Bleesing JJ, Mustillo P, Stephens M, Rueda CM, Chougnet CA, Hoebe K, McElwee J, Hughes JD, Karakoc-Aydiner E, Matthews HF, Price S, Su HC, Rao VK, Lenardo MJ, Jordan MB. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349:436-440.
Lindsley AW, Qian Y, Valencia CA, Shah K, Zhang K, Assa’ad A. Combined Immune Deficiency in a Patient with a Novel NFKB2 Mutation. J Clin Immunol. 2014 Nov;34(8):910-5.
Valencia CA, Indugula SR, Mathur A, Wei C, Brown J, Dell S, Cole I, Connor J, Zhang K. Misleading results from saliva samples of post bone marrow transplanted patients in exome analyses. Published Blood. 2014 Jul 24;124(4):660-1.
Zhang K, Chadrakasan S, Chapman H, Valencia CA, Husami A, Kissell D, Johnson JA, Filipovich AH. Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis. Blood. 2014 Aug 21;124(8):1331-4.
Qian Y, Johnson J, Connor J, Valencia CA, Barasa N, Schubert J, Husami A, Kissell D, Zhang G, Weirauch M, Filipovich A, Zhang K. The 253-kb inversion and deep intronic mutations in UNC13D are present in North American patients with familial hemophagocytic lymphohistiocytosis 3. Pediatric Blood Cancer. 2014;61:1034–1040.
Theru Arumugam S, Husami A, Kissell D, Zhang W, Keddache M, Black AP, Tinkle BT, Greinwald JH, Zhang K. Performance Evaluation of the Next-Generation Sequencing Approach for Molecular Diagnosis of Hereditary Hearing Loss. Otolaryngol Head Neck Surg. 2013 Jun;148(6):1007-16.
Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, Villanueva J, Risma KA, Wei Q, Klein PS, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011;118:5794-5798
Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, Bleesing JJ, Filipovich AH, Zhang K. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer. 2010;55:134-140.
Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, Binstadt BA, Filipovich A, Grom AA. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum. 2008;58:2892-2896.
Zhang K, Johnson JA, Biroschak J, Villanueva J, Lee SM, Bleesing JJ, Risma KA, Wenstrup RJ, Filipovich AH. Familial haemophagocytic lymphohistiocytosis in patients who are heterozygous for the A91V perforin variation is often associated with other genetic defects. Int J Immunogenet. 2007;34:231-233.
Peggy O. Clark, MSN, APRN, PNP Pediatric Nurse Practitioner, Division of Neurology 513-636-8467 email@example.com
Pediatric Nurse Practitioner, Division of Neurology
Peggy Clark received her undergraduate nursing degree from the University of Kentucky. She graduated with honors from the university’s Honors Program, served as student senator for the College of Nursing, and was named Outstanding Nursing Student in her senior year. She has worked at Cincinnati Children’s Hospital Medical Center since receiving her undergraduate nursing degree, and has been a clinical nurse, assistant head nurse, educational nurse specialist, and a nurse practitioner with an epilepsy research focus since 1995. She is a member of the Children’s Medical Center Federal Credit Union Board of Directors, The Greater Cincinnati Epilepsy Foundation Board of Directors, and the APN Professional Inquiry Council.
BSN: University of Kentucky, 1979.
MSN: University of Kentucky, 1985.
Post-Masters Clinical Scholar (PNP): University of Kentucky, 1995.
Certification: American Nurses Credentialing Center, 1995.
Cynthia A. Prows, MSN, APRN, CNS
Genetics Clinical Nurse Specialist, Division of Human Genetics 513-636-7963 firstname.lastname@example.org
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center